News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Shkreli's Retrophin, LLC Makes $75 Million Hostile Bid for CA-Based Transcept Pharmaceuticals, Inc. (TSPT)



9/19/2013 8:07:02 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Martin Shkreli made a lot of waves challenging the boards of various biotechs and drugmakers a few years ago as a hedge fund manager. Now his rare disease startup, Retrophin, is taking a similarly aggressive approach to M&A. New York-based Retrophin (OTCBB: RTRX) said just after the market closed today that it has made a hostile bid to acquire Point Richmond, CA-based Transcept Pharmaceuticals (NASDAQ: TSPT) at $4.00 per share.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES